Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, and myasthenia gravis are now recruiting.

Investor Relations

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2023

Sign Up For Email Alerts

Receive updates straight into your inbox

Company Overview

Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Our proprietary Cabaletta Approach to B cell Ablation (CABA®) platform is designed to provide durable, potentially curative, responses with one-time administration, with the possibility of eliminating the need for chronic immune suppressive therapies. We believe the CABA™ platform has potential applicability across a broad range of autoimmune diseases. It encompasses two strategies: the Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) approach as well as our initial Chimeric AutoAntibody Receptor T (CAART) approach. Our lead CARTA candidate, CABA-201, is an investigational 4-1BB-containing CD19-CAR T cell therapy based on a clinically evaluated fully human CD19 binder. CABA-201 is currently under development for systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis as well as other autoimmune diseases with high unmet need. Through our initial CAART platform, we are developing our clinical-stage candidates, including DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK myasthenia gravis. Our goal is to leverage our team’s expertise in autoimmunity and T cell therapy and our network of collaborators to rapidly develop and launch our portfolio of engineered T cell therapy candidates to transform the treatment of autoimmune diseases.

Investor Contact Information


Cabaletta Bio, Inc.
2929 Arch Street
Suite 600
Philadelphia, PA 19104

Investor Relations

Anup Marda
Chief Financial Officer

Stern Investor Relations, Inc.
William Gramig

Transfer Agent

American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, NY 11219
T: 718-921-8200 x4801